ESMO 2025

I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Agenda

Medical Materials

12:10 PM

Duration 10mins Hamburg Auditorium

SKYSCRAPER-07: A phase III, randomised study of atezolizumab (atezo) with or without tiragolumab (tira) in patients (pts) with unresectable esophageal squamous cell carcinoma (ESCC) that has not progressed following definitive concurrent chemoradiotherapy (dCRT)

Amy Cai, Anthony Turpin, Baosheng Li, Byoung Chul Cho, Chih-Hung Hsu, Edward Cha, Florian Lordick, Ian Chau, Jianxin Fan, Karyn Goodman, Li Zhang, Lucjan Wyrwicz, Luhua Wang, Manish Shah, Ming Huang Chen, Muro Kei, Qiong Wu, Rui-Hua Xu, Sarah Kim, Shegan Gao

Oncology | Esophageal Squamous Cell Carcinoma

03:00 PM

Duration 5mins Heidelberg Auditorium

Single-agent divarasib experience in patients with KRAS G12C-positive pancreatic adenocarcinoma (panc), cholangiocarcinoma (cholangio), and other solid tumors

Krebs M.G.

Oncology | Pancreatic Cancer

07:00 AM

Duration 60mins Berlin, Germany

ESMO treatment (tx) guideline adherence in patients (pts) with lung cancer (LC) with EGFR or ALK (EGFR/ALK) alterations: a WAYFIND-R registry-based study

Dienstmann R.

Oncology | Lung Cancer

07:25 AM

Duration 10mins Bonn Auditorium

SKYSCRAPER-03: Phase 3, open-label, randomised study of atezolizumab + tiragolumab vs durvalumab in locally advanced, unresectable, stage III non-small cell lung cancer after platinum-based concurrent chemoradiation

Rafal Dziadziuszko

Oncology | Non-Small Cell Lung Cancer

08:15 AM

Duration 10mins Berlin Auditorium

Giredestrant, an oral selective oestrogen receptor antagonist and degrader, in combination with everolimus in patients with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the Phase III evERA BC trial

Erica Mayer

Oncology | Her2 Negative Breast Cancer

10:00 AM

Duration 45mins Berlin, Germany

IMscin001 final analysis: a randomised phase 3 study of subcutaneous (SC) versus intravenous (IV) atezolizumab (atezo) in patients with locally advanced or metastatic non- small cell lung cancer (NSCLC)

Enriqueta Felip, Fiona Young, Luis Herraez-Baranda, Mauricio Burotto, Nadia Tosti, Renzo Alvarez, Teresa Barata, Yotsawaj Runglodvatana, Yovanna Castro, Zanete Zvirbule

Oncology | Non-Small Cell Lung Cancer

Duration 45mins Berlin, Germany

Machine learning classification of small cell lung cancer using plasma multiomics in IMPower133

M. Reck

Oncology | Small Cell Lung Cancer

03:15 PM

Duration 5mins Hamburg Auditorium

Patterns of disease progression (PD) and efficacy associated with tumour burden from the Phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in ES-SCLC

Paz Ares

Oncology | Small Cell Lung Cancer

08:55 AM

Duration 10mins Berlin Auditorium

IMbrave152/SKYSCRAPER-14: a phase III study of first-line tiragolumab + atezolizumab + bevacizumab vs placebo + atezolizumab + bevacizumab for patients with untreated locally advanced or metastatic hepatocellular carcinoma

R. Finn

Oncology | Hepatocellular Carcinoma

10:00 AM

Duration 45mins Berlin, Germany

Safety of atezolizumab with or without tiragolumab following neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer (NEOTERIC Study): a randomized, open-label phase II study

Xu J.

Oncology | Rectal cancer

Duration 45mins Berlin, Germany

Phase I study of ERY974 + atezolizumab (atezo) + bevacizumab (bev) in patients with locally advanced or metastatic hepatocellular carcinoma (HCC)

Ann-Lii Cheng Hideki Ueno, Sadahisa Ogasawara, Chia-Jui Yen, Masatoshi Kudo, Teng-Yu Lee, Masafumi Ikeda, Yin-Hsun Feng, Chao-Hung Hung, Makoto Ueno, Daisuke Shimizu, Hitomi Takeshita, Hiroaki Tomita, Mikiko Nakamura, Chika Ogami, Chun-Yen Lin

Oncology | Hepatocellular Carcinoma

02:45 PM

Duration 5mins Cologne Auditorium

SKYSCRAPER-09: Phase 2, non-comparative, randomised study of tiragolumab + atezolizumab and placebo + atezolizumab as first-line treatment in patients with recurrent/metastatic PD-L1+ squamous cell carcinoma of the head and neck(atezo) and atezo + placebo (pbo) as first-line (1L) treatment in patients (pts) with recurrent/metastatic PD-L1+ squamous cell carcinoma of the head and neck (R/M SCCHN)

Amanda Psyrri, Amaury Daste, Arunee Dechaphunkul, Ching-Yun Hsieh, Chipman R Stroud, Christina Matheny, Christophe Le Tourneau, Deborah Wong, Denise Bradley (Richardson), Floriane Alias, JEROME FAYETTE, Kevin Harrington, Maura Gillison, Melissa Johnson, Nuttapong Ngamphaiboon, Se Hoon Lee, Tien Hoang, Wei Zhang, Yibing Yan

Oncology | Squamous Cell Cancer

10:00 AM

Duration 45mins Berlin, Germany

Phase I/Ib trial of inavolisib▼ (INAVO) + pertuzumab (P) + trastuzumab (H) for PIK3CA-mutated (mut), HER2-positive advanced breast cancer (HER2+ aBC)

Philippe L. Bedard

Oncology | Breast Cancer

Duration 45mins Berlin, Germany

Interim analysis of giredestrant (GIRE) + inavolisib (INAVO) in MORPHEUS Breast Cancer (BC): A Phase Ib/II study of GIRE treatment (rx) combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)

Hope S. Rugo

Oncology | Estrogen Receptor Positive Breast Cancer

12:50 PM

Duration 5mins Hamburg Auditorium

Updated results from the phase III ALINA study of adjuvant alectinib vs chemotherapy (chemo) in patients (pts) with early-stage ALK+ non-small cell lung cancer (NSCLC)

Agata Higgerson, Andres Cardona, Astrid Scalori, Benjamin Solomon, Dae Ho Lee, FABRICE BARLESI, FILIPPO DE MARINIS, Hidehito Horinouchi, Igor Bondarenko, Jin Seok Ahn, Jong-Seok Lee, Makoto Nishio, Maria Rita Migliorino, Maximilian Hochmair, Rafał Dziadziuszko, Tingting Xu, Virginia McNally, Weimin Mao, Wenzhao Zhong, Yi-Long Wu

Oncology | Non-Small Cell Lung Cancer

02:30 PM

Duration 12mins Berlin Auditorium

IMvigor011: a randomised Phase 3 trial of adjuvant atezolizumab (atezo) vs placebo in circulating tumour (ct)DNA-based molecular residual disease (MRD) positive muscle-invasive bladder cancer (MIBC) post-radical cystectomy (RC)

Powles T

Oncology | Muscle Invasive Urothelial Cancer

Coming soon

I am a healthcare professional

Notice

Cookies

External site

ESMO 2025